Evidence map›Paper›PMID 35519217›Full record

ReviewRSC advances2020

The oxazolomycin family: a review of current knowledge.

Patrik Oleksak, Jozef Gonda, Eugenie Nepovimova, Kamil Kuca, Kamil Musilek

Abstract readReview
In one paragraph

Review in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Spirocyclic β-lactone secondary metabolites modulate spliceosome function.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Biosynthesis in Streptomyces sp. NRRL S-1813 and regulation between oxazolomycin A and A2.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  3. Article
  4. Oxazolomycins produced byRSC advances · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Patrik OleksakUniversity of Hradec Kralove, Faculty of Science, Department of Chemistry Rokitanskeho 62 500 03 Hradec Kralove Czech Republic kamil.musilek@uhk.cz.ORCID https://orcid.org/0000-0002-6850-7671
Jozef GondaPavol Jozef Safarik University, Faculty of Science, Department of Organic Chemistry Moyzesova 11 040 01 Kosice Slovak Republic.ORCID https://orcid.org/0000-0002-2424-2181
Eugenie NepovimovaUniversity of Hradec Kralove, Faculty of Science, Department of Chemistry Rokitanskeho 62 500 03 Hradec Kralove Czech Republic kamil.musilek@uhk.cz.ORCID https://orcid.org/0000-0003-0281-246X
Kamil KucaUniversity of Hradec Kralove, Faculty of Science, Department of Chemistry Rokitanskeho 62 500 03 Hradec Kralove Czech Republic kamil.musilek@uhk.cz.ORCID https://orcid.org/0000-0001-9664-1109
Kamil MusilekUniversity of Hradec Kralove, Faculty of Science, Department of Chemistry Rokitanskeho 62 500 03 Hradec Kralove Czech Republic kamil.musilek@uhk.cz.ORCID https://orcid.org/0000-0002-7504-4062

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxazolomycin A and neooxazolomycin were firstly isolated in 1985 by the group of Uemura

Identifiers

PMID35519217
PMCPMC9057759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.